The CNS Company, Stirling, Scotland, UK
Posters & Accepted Abstracts: J Neurol Disord
The failure rate for drugs in late-stage clinical trials is high; however, in CNS disorders it is spectacularly high. For example, in AlzheimerÔ??s disease, 99.6% of drugs in phase III clinical trials have failed. Since the burden of CNS disease is extremely high, the demand for treatments exists and is ever growing. From all the trial failures, there are, therefore, a huge amount of lessons that can be learnt if you are willing to look honestly at what has gone wrong and consider taking a different path. This talk will look at the lessons that can be learned from poor patient selection, endpoint selection and poor trial design resulting in high screen failures and withdrawals.
E-mail: [email protected]